|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,259.00 INR | +1.53% |
|
-0.08% | +11.04% |
| 03/08 | Glenmark Pharmaceuticals Limited, Q1 2027 Earnings Call, Aug 03, 2026 | |
| 31/07 | India's Glenmark Pharma posts higher quarterly profit on strong demand | RE |
| Market Cap | 63TCr 660.09Cr 573.16Cr 534.4Cr 490.92Cr 928.46Cr 938.65Cr 6.3TCr 2.46TCr 31TCr 2.48TCr 2.42TCr 1,04000Cr | P/E 2026 |
44.2x | P/E 2027 * | 26.8x |
|---|---|---|---|---|---|
| Enterprise Value | 59TCr 618.78Cr 537.29Cr 500.96Cr 460.2Cr 870.36Cr 879.91Cr 5.91TCr 2.31TCr 29TCr 2.32TCr 2.27TCr 97TCr | EV / Sales 2026 |
3.51x | EV / Sales 2027 * | 3.65x |
| Free-Float |
51.04% | Yield 2026 |
0.12% | Yield 2027 * | 0.17% |
Last Transcript: Glenmark Pharmaceuticals Limited
| 1 day | +1.57% | ||
| 1 week | -0.08% | ||
| Current month | +1.16% | ||
| 1 month | -0.48% | ||
| 3 months | -6.53% | ||
| 6 months | +14.76% | ||
| Current year | +11.04% |
| 1 week | 2,162 |  | 2,270.2 |
| 1 month | 2,162 | | 2,326.1 |
| Current year | 1,842 | | 2,474 |
| 1 year | 1,792.6 | | 2,474 |
| 3 years | 722.1 | | 2,474 |
| 5 years | 348.5 | | 2,474 |
| 10 years | 161.65 | | 2,474 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 01/01/2000 | |
Anurag Mantri
DFI | Director of Finance/CFO | 54 | 27/05/2025 |
Indrajit Bose
PSD | President | - | 15/09/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Cherylann Pinto
BRD | Director/Board Member | 58 | - |
| Chairman | 56 | 12/05/2011 | |
| Director/Board Member | 85 | 14/08/2009 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.53% | -0.08% | +10.10% | +176.95% | 660.09Cr | |
| -1.22% | -2.28% | +19.14% | +67.51% | 4.95TCr | |
| -1.75% | +2.61% | +59.16% | +125.42% | 4.01TCr | |
| -0.08% | -0.97% | -2.65% | +19.32% | 1.24TCr | |
| -0.79% | -1.03% | +15.71% | +69.58% | 1.18TCr | |
| +1.44% | -0.38% | +31.82% | +134.08% | 910.08Cr | |
| -0.26% | -7.65% | +36.44% | -15.53% | 688.06Cr | |
| +1.59% | +3.33% | +15.58% | +33.74% | 693.63Cr | |
| -.--% | +0.14% | - | - | 678.76Cr | |
| -.--% | -1.95% | - | - | 572.55Cr | |
| Average | -0.05% | +0.60% | +23.16% | +76.38% | 1.56TCr | |
| Weighted average by Cap. | -0.70% | +1.40% | +29.20% | +83.34% |
| 2026 | 2027 * | |
|---|---|---|
| Net sales | 15TCr 160.96Cr 139.76Cr 130.31Cr 119.71Cr 226.4Cr 228.89Cr 1.54TCr 600.58Cr 7.65TCr 604.46Cr 591.22Cr 25TCr | 17TCr 176.61Cr 153.35Cr 142.98Cr 131.35Cr 248.42Cr 251.14Cr 1.69TCr 658.98Cr 8.4TCr 663.23Cr 648.7Cr 28TCr |
| Net income | 2.05TCr 22Cr 19Cr 17Cr 16Cr 30Cr 31Cr 206.02Cr 81Cr 1.03TCr 81Cr 79Cr 3.4TCr | 2.33TCr 25Cr 21Cr 20Cr 18Cr 35Cr 35Cr 234.23Cr 92Cr 1.17TCr 92Cr 90Cr 3.87TCr |
| Net Debt | -3.93TCr -41Cr -36Cr -33Cr -31Cr -58Cr -59Cr -394.28Cr -154.13Cr -1.96TCr -155.13Cr -151.73Cr -6.51TCr | -1.45TCr -15Cr -13Cr -12Cr -11Cr -21Cr -22Cr -145.22Cr -57Cr -723.49Cr -57Cr -56Cr -2.4TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/26/05 | ₹2,259.00 | +1.53% | 3,88,492 |
| 04/26/04 | ₹2,225.00 | -0.22% | 4,44,946 |
| 03/26/03 | ₹2,230.00 | -0.17% | 13,07,223 |
| 31/26/31 | ₹2,233.90 | +1.99% | 3,71,153 |
| 30/26/30 | ₹2,190.30 | -3.16% | 4,51,791 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GLENMARK Stock
Select your edition
All financial news and data tailored to specific country editions
